Leon H. Kircik, MD

In the final part of this Frontline Forum series, James Del Rosso, DO; Hilary Baldwin, MD; Neal Bhatia, MD; Christopher Bunick, MD, PhD; and Leon Kircik, MD, discuss the use of clascoterone cream 1%, differences in isotretinoin formulations, targeting sebum production, acne guidelines for patient care, and more.

In part 3 of this Frontline Forum series, James Del Rosso, DO; Hilary Baldwin, MD; Neal Bhatia, MD; Christopher Bunick, MD, PhD; and Leon Kircik, MD, discuss the use of clascoterone cream 1%, differences in isotretinoin formulations, targeting sebum production, acne guidelines for patient care, and more.

In part 2 of this Frontline Forum series, James Del Rosso, DO; Hilary Baldwin, MD; Neal Bhatia, MD; Christopher Bunick, MD, PhD; and Leon Kircik, MD, discuss the use of clascoterone cream 1%, differences in isotretinoin formulations, targeting sebum production, acne guidelines for patient care, and more.

In part 1 of this Frontline Forum series, James Del Rosso, DO; Hilary Baldwin, MD; Neal Bhatia, MD; Christopher Bunick, MD, PhD; and Leon Kircik, MD, discuss the pathogenesis of acne vulgaris, the use of clascoterone cream 1%, differences in isotretinoin formulations, targeting sebum production, acne guidelines for patient care, and more.

An expert in dermatology shares his opinion on the multiple formulations of isotretinoin and the importance of generic vs brand compositions.

Dr Leon Kircik, discusses the novel treatment Clascoterone cream 1%, an androgen receptor agonist, and the utility of this treatment in the management of acne.

Leon Kircik, MD, shares his opinion on the role and use of treatment guidelines by healthcare practitioners in the management of their patients.

In the final part of this Frontline Forum series, Joshua Zeichner, MD, FAAD; Hilary Baldwin, MD; Zoe Diana Draelos, MD; Aaron S. Farberg, MD, FAAD; and Leon H. Kircik, MD, discuss the main pillars of acne and topical treatments available for patients with acne.

In part 3 of this Frontline Forum series, Joshua Zeichner, MD, FAAD; Hilary Baldwin, MD; Zoe Diana Draelos, MD; Aaron S. Farberg, MD, FAAD; and Leon H. Kircik, MD, discuss the main pillars of acne and topical treatments available for patients with acne.

In part 2 of this Frontline Forum series, Joshua Zeichner, MD, FAAD; Hilary Baldwin, MD; Zoe Diana Draelos, MD; Aaron S. Farberg, MD, FAAD; and Leon H. Kircik, MD, discuss the main pillars of acne and topical treatments available for patients with acne.

In part 1 of this Frontline Forum series, Joshua Zeichner, MD, FAAD; Hilary Baldwin, MD; Zoe Diana Draelos, MD; Aaron S. Farberg, MD, FAAD; and Leon H. Kircik, MD, discuss the main pillars of acne and topical treatments available for patients with acne.

Dr Leon Kircik, comments on the impact the multiple formulations of isotretinoin had on acne care; and highlights the efficacy differences between generic vs brand formulations.

Leon Kircik, M.D., discusses the indication of isotretinoin for use in patients suffering from acne, highlighting the difference between high and low dose administration needs.

EDITOR'S NOTE: Dr. Leon Kircik is replying to a clarification from Chester Valley Pharmaceuticals that ran in our November issue on an article in the October issue, "Vehicles often drive treatment of difficult ailments." Atopiclair is Chester Valley Pharmaceutical's product. While Dr. Kircik was not the author of the article (he was interviewed by Senior Staff Correspondent John Jesitus) he did see the article before it went to press for his approval, as is Dermatology Times' standard practice with clinical articles.